Key takeaway
What This Development Means
The UK’s latest carcinogenicity guidance proposes a bold shift from animal testing towards more human-relevant, data-driven assessments. This move could reduce costs, enhance compliance, and improve public health communication across industries handling chemicals.
What is the UK’s new stance on carcinogenic risk assessment?
The UK’s Committee on Carcinogenicity is encouraging a departure from binary carcinogen classifications and long-term rodent studies, advocating instead for human-relevant, multi-source data approaches to better assess chemical cancer risk.
How will this impact manufacturers and regulators?
The guidance offers opportunities to streamline regulatory submissions, reduce reliance on animal data, and adopt advanced testing methodologies—benefiting manufacturers, regulators, and public health professionals alike.
The UK’s Committee on Carcinogenicity (COC) has issued new guidance calling for a fundamental shift in how the risk of cancer caused by chemicals is assessed. Published in May 2025, the guidance challenges the long-standing reliance on two-year rodent studies and binary classifications. The update encourages industry and regulators across the chemicals value chain to adopt human-relevant, evidence-based approaches that enhance health protection while reducing animal testing.
New Approach To Assessing Chemical Carcinogenicity
Guidance Statement G11 from the COC signals a major policy shift, stating that traditional long-term animal assays are no longer sufficient to determine the real-world risk of cancer in humans. The COC argues that the conventional method—classifying chemicals simply as ‘carcinogen’ or ‘non-carcinogen’—lacks the nuance needed to assess exposure-driven risk.
Instead, the committee is promoting the integration of New Approach Methodologies (NAMs), weight-of-evidence assessments, and early-stage data to identify potential hazards more accurately. These methods are seen as better aligned with real-world exposures and regulatory priorities, especially in sectors such as pharmaceuticals, agrochemicals, and cosmetics.
Industry And Regulatory Impacts
This change could significantly affect stakeholders across the manufacturing value chain. For example, cosmetics companies have already adapted due to the EU ban on animal testing post-2013. Meanwhile, projects like the “Rethinking Carcinogenicity Assessment for Agrochemicals Project (ReCAAP)” illustrate that effective cancer risk analysis can be achieved without two-year studies.
The guidance highlights that industry is already generating early-phase data before mandatory animal tests. Leveraging this data could reduce regulatory burdens, lower costs, and accelerate approvals, all while enhancing human health protections.
However, the COC acknowledges that some in industry may hesitate to submit non-conventional data due to regulatory uncertainty or lack of harmonisation. The committee is actively seeking case studies and proposals to guide future updates and validate alternative methods.
Better Public Communication On Cancer Risks
The binary classification system often fails to communicate actual health risks to the public. The COC stresses that clearer, more informative messages about chemical exposure and cancer risk are essential. Shifting to nuanced assessments can improve public trust while supporting better regulatory decision-making.
Related Articles
EPA Proposes New Regulations On 1-Bromopropane
The rule would prohibit the manufacture, processing, and distribution of 1-BP for all consumer uses, except for certain industrial applications.
Understanding The EPA's New Regulations On Methylene Chloride And Impacts On Industries
The regulation identifies specific uses of Methylene Chloride that are either prohibited outright or subject to stringent controls.
EPA Finalises Stricter Regulations On TCE And PCE
The EPA introduces strict bans and controls on trichloroethylene (TCE) and perchloroethylene (PCE), aiming to reduce cancer risks and protect workers.
